ZA923639B - Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules - Google Patents

Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Info

Publication number
ZA923639B
ZA923639B ZA923639A ZA923639A ZA923639B ZA 923639 B ZA923639 B ZA 923639B ZA 923639 A ZA923639 A ZA 923639A ZA 923639 A ZA923639 A ZA 923639A ZA 923639 B ZA923639 B ZA 923639B
Authority
ZA
South Africa
Prior art keywords
bdnf
treatment
motor neuron
molecules
members
Prior art date
Application number
ZA923639A
Other languages
English (en)
Inventor
Vivien Wong
Wong Vivien
Czeslaw Radziejewski
Radziejewski Czeslaw
Peter Distefano
Distefano Peter
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Publication of ZA923639B publication Critical patent/ZA923639B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Water Treatment By Sorption (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA923639A 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules ZA923639B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10

Publications (1)

Publication Number Publication Date
ZA923639B true ZA923639B (en) 1993-02-24

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA923639A ZA923639B (en) 1991-07-10 1992-05-19 Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules

Country Status (20)

Country Link
EP (2) EP0593516B1 (xx)
JP (1) JPH06509094A (xx)
CN (1) CN1065768C (xx)
AT (1) ATE202939T1 (xx)
AU (2) AU675409B2 (xx)
CA (1) CA2113083A1 (xx)
DE (1) DE69231930T2 (xx)
DK (1) DK0593516T3 (xx)
ES (1) ES2157903T3 (xx)
FI (1) FI940098A (xx)
GR (1) GR3036776T3 (xx)
HU (1) HUT70275A (xx)
IE (1) IE921602A1 (xx)
IL (1) IL101928A0 (xx)
NO (1) NO940084L (xx)
PT (1) PT100501A (xx)
RU (1) RU94016525A (xx)
SK (1) SK2694A3 (xx)
WO (1) WO1993001300A1 (xx)
ZA (1) ZA923639B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025684A1 (en) * 1992-06-12 1993-12-23 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
CA2408255A1 (en) 2000-05-05 2001-11-15 Marie T. Filbin Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
RU2434636C2 (ru) * 2004-11-17 2011-11-27 Ньюралстем, Инк. Трансплантация нервных клеток для лечения нейродегенеративных состояний
WO2008156418A1 (en) * 2007-06-19 2008-12-24 Astrazeneca Ab A method for screening or diagnosis of postpolio syndrome and fibromyalgia
MX2010001395A (es) * 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
WO2014111525A2 (en) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl New combination therapies for treating nervous system diseases
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
WO2023164311A2 (en) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
NO940084D0 (no) 1994-01-10
EP0593516B1 (en) 2001-07-11
DE69231930T2 (de) 2002-04-11
GR3036776T3 (en) 2002-01-31
FI940098A (fi) 1994-03-10
CN1065768C (zh) 2001-05-16
RU94016525A (ru) 1996-06-10
FI940098A0 (fi) 1994-01-10
DE69231930D1 (de) 2001-08-16
PT100501A (pt) 1993-09-30
IL101928A0 (en) 1992-12-30
CN1071585A (zh) 1993-05-05
ATE202939T1 (de) 2001-07-15
NO940084L (no) 1994-03-08
SK2694A3 (en) 1995-02-08
EP0755682A1 (en) 1997-01-29
IE921602A1 (en) 1993-01-13
WO1993001300A1 (en) 1993-01-21
ES2157903T3 (es) 2001-09-01
DK0593516T3 (da) 2001-09-17
AU2009592A (en) 1993-02-11
JPH06509094A (ja) 1994-10-13
EP0593516A4 (en) 1995-01-18
EP0593516A1 (en) 1994-04-27
HUT70275A (en) 1995-09-28
AU7067696A (en) 1997-01-16
CA2113083A1 (en) 1993-01-21
HU9400063D0 (en) 1994-06-28
AU675409B2 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
FI108146B (fi) Biologisesti aktiivisten, neurotrofisten NGF/BDNF-sarjan yhdistelmäproteiinien valmistus
IL101928A0 (en) Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
ZA886471B (en) Conjugates of cytokines with imunologulins
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
HUT47432A (en) Process for correcting disorders of immun-complexes of the circulation systhem and monocytes with double-line dns
EP0295280A4 (en) Use of protoporphyrin and stannic mesoporphyrin for the manufacture of a medicament for the treatment of psoriasis.
GR3025134T3 (en) Process for preparing a concentrate of blood coagulation factor XI with high specific activity, appropriate for therapeutic use
AU7426487A (en) Method of treating depression using d-fenfluramine
Gordon The relationship between language and behaviour.
Aurela A systematic storytelling therapy.
DE3476736D1 (en) Use of an antihypoxidoticum with cerebral and peripheral effect
Dienstfrey Neal Miller, the dumb autonomic nervous system, and biofeedback.
UA20012A (uk) Спосіб лікуваhhя постекстракційhої запальhої ексудативhої реакції у хворих hа катаракту
AU6725387A (en) Drugs for the treatment and cure of all infectious diseases caused by pathogenic virulent micro-organisms